How well does Xagrid(bictegravir/emtricitabine/tenofovir alafenamide) work?

Clinical trials demonstrate that BIKTARVY effectively maintains virologic suppression in HIV-1 patients.

Clinical Efficacy

In adults with no antiretroviral history, BIKTARVY showed high efficacy, with over 80% achieving HIV-1 RNA less than 50 copies/mL after 144 weeks. Similar results were observed in virologically suppressed adults who switched to BIKTARVY, with low rates of virologic failure. Pediatric studies also supported efficacy, where most participants remained suppressed. The drug led to increased CD4+ cell counts, indicating immune improvement. No significant resistance development was noted in trials, making it a reliable option for long-term HIV management across age groups.